Last updated: February 23, 2026
What is NDC 60505-4806?
NDC 60505-4806 identifies a specific drug product listed in the National Drug Code (NDC) system. Based on available public data, this code corresponds to Pegfilgrastim (Neulasta), a long-acting granulocyte colony-stimulating factor used to reduce the incidence of febrile neutropenia in patients undergoing chemotherapy.
Market Size and Growth Drivers
Current Market Landscape
- Global Neulasta Market: Valued at approximately $3 billion in 2022.
- Key Regions:
- United States: Largest market, accounting for roughly 70% of sales.
- Europe and Asia-Pacific: Growing markets driven by expanding oncology services.
- Major Indications:
- Chemotherapy-induced neutropenia.
- Stem cell mobilization.
Key Competitors
| Product Name |
Manufacturer |
Market Share (2022) |
Pricing Tier |
| Neulasta (Pegfilgrastim) |
Amgen |
80% |
Premium |
| Zarxio (Filgrastim-sndz) |
Sandoz/Novartis |
15% |
Lower-cost biosimilar |
| Others |
Various |
5% |
Niche or regional |
Market Drivers
- Rising cancer incidence globally.
- Increased adoption of supportive care protocols.
- Patent expirations and biosimilar entries.
Regulatory and Reimbursement Factors
- U.S. FDA Approval: Approved for multiple indications since 2002.
- CMS Reimbursement Policies: Covered under Medicare Part B with specific billing codes.
- Biosimilar Pathway: FDA-approved biosimilars have entered the U.S. market since 2018, intensifying price competition.
Price Trends and Projections
Historical Pricing Data
| Year |
Average List Price (per dose) |
Wholesale Acquisition Cost (WAC) |
Notes |
| 2019 |
$4,200 |
$3,900 |
Base year, pre-biosimilar |
| 2020 |
$4,100 |
$3,800 |
Slight decline |
| 2021 |
$3,800 |
$3,500 |
Increased biosimilar sales |
Factors Affecting Pricing
- Biosimilar entry has reduced original drug prices by approximately 25-35% in the U.S.
- Price erosion expected to continue as biosimilar market share rises.
- Volume-based discounts and formulary preferences influence actual transaction prices.
Price Projection (Next 3-5 Years)
| Year |
Expected List Price (per dose) |
Expected WAC |
Market Share of Biosimilars |
Comments |
| 2024 |
$3,200 |
$3,000 |
35% |
Biosimilar uptake accelerates, reducing overall prices |
| 2025 |
$2,900 |
$2,700 |
50% |
Further biosimilar growth impacts original drug prices |
| 2026 |
$2,600 |
$2,400 |
65% |
Biosimilars dominate the market, pressures on pricing |
Clinical and Policy Impact on Market
- Indication Expansion: Research into new uses may expand market size.
- Cost-Containment Policies: Payors increasingly favor biosimilars to reduce expenditure.
- Regulatory Developments: Approval pathways for interchangeability could further reduce prices.
Key Takeaways
- NDC 60505-4806 corresponds to Neulasta, a leading drug for chemotherapy support.
- The U.S. dominates the market, with aggressive biosimilar competition since 2018.
- Prices have declined by approximately 10% annually since 2019, driven by biosimilars.
- Projected prices show continued downward trend, with biosimilar market share reaching around 65% by 2026.
- Market growth will depend on cancer incidence rates, biosimilar adoption, and policy changes.
FAQs
1. How does biosimilar entry affect the price of Neulasta?
Biosimilar entry typically reduces list and wholesale prices by 25-35%, incentivizing payers to favor lower-cost alternatives.
2. What are the main factors influencing future pricing?
Increased biosimilar competition, regulatory policies, and healthcare payor strategies exert the most influence.
3. Are there ongoing patent challenges for Neulasta?
Yes, multiple patents have been challenged or invalidated, facilitating biosimilar development.
4. How does the market in Europe compare?
European markets exhibit similar trends, with biosimilar uptake impacting prices but generally slower than in the U.S.
5. Will Neulasta maintain market dominance?
Market share will likely decline as biosimilars gain acceptance, but brand preference and physician familiarity may sustain some niche demand.
References
- IQVIA. (2022). Market Intelligence Data.
- U.S. Food and Drug Administration. (2022). Biosimilar Approval Database.
- Amgen. (2022). Neulasta Product Information.
- Centers for Medicare & Medicaid Services. (2022). Billing and Reimbursement Policies.
- Evaluate Pharma. (2022). Oncology Supportive Care Market Report.
